BERLIN & SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors. Vividion is a biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies with the potential to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders.

柏林和圣地亚哥--（商业新闻短讯）--Vividion Therapeutics，Inc.（Vividion）今天宣布，它已经开始在一项I期临床试验中给患者服用VVD-130850，这是一种用于治疗晚期实体瘤和血液肿瘤的研究性口服STAT3抑制剂。Vividion是一家生物制药公司，是拜耳公司的全资和独立运营子公司，利用创新的发现技术，有可能解锁高价值，传统上不可药用的目标，并为毁灭性癌症和免疫疾病提供精确治疗。

The start of the trial represents another major milestone for Vividion’s innovative chemoproteomics platform..

试验的开始代表了Vividion创新化学蛋白质组学平台的另一个重要里程碑。。

“The initiation and dosing of the first clinical trial with our STAT3 inhibitor program marks a major inflection point for Vividion as this is the second program from our platform that we have advanced into the clinic in just a few months. We are proud of the progress we have made in a relatively short amount of time with a pipeline consisting of previously undruggable protein targets for prominent oncology and immunology diseases,” said Aleksandra Rizo M.D., Ph.D., Chief Executive Officer of Vividion..

“STAT3抑制剂项目的首次临床试验的启动和给药标志着Vividion的一个重大转折点，因为这是我们平台在短短几个月内进入临床的第二个项目。我们为我们在相对较短的时间内取得的进展感到骄傲，这条管道由promi以前不可药用的蛋白质靶标组成Vividion首席执行官AleksandraRizo医学博士说。。

“We are leveraging Vividion’s innovative chemoproteomics drug discovery technology to develop new therapies that are addressing high profile cancer targets with the potential to stop or reverse the progression of disease,” said Christian Rommel, Ph.D., Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Research and Development.

拜耳制药部执行委员会成员兼研发负责人克里斯蒂安·隆美尔博士说：“我们正在利用Vividion创新的化学蛋白质组学药物发现技术开发新疗法，以解决备受关注的癌症靶点，并有可能阻止或逆转疾病的进展。”。

“For millions of patients and their families, cancer continues to be a devastating disease, and new treatments are needed to address key drivers of tumor cell survival and growth. The start of the clinical development of Vividion’s STAT3 inhibitor program takes us one step closer to a potentially meaningful new treatment for cancer patients.”.

“对于数百万患者及其家人来说，癌症仍然是一种毁灭性的疾病，需要新的治疗方法来解决肿瘤细胞存活和生长的关键驱动因素。Vividion STAT3抑制剂项目的临床开发开始，使我们离癌症患者潜在有意义的新治疗更近了一步。”。

VVD-130850 is an oral small molecule inhibitor of STAT3 binding to a novel allosteric pocket leading to direct inhibition of DNA binding and expression of STAT3 target genes in cancer cells. The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-130850 in patients with advanced solid and hematologic tumors as a single-agent and in combination with immune checkpoint inhibition..

VVD-130850是STAT3与新型变构口袋结合的口服小分子抑制剂，可直接抑制癌细胞中DNA结合和STAT3靶基因的表达。I期临床试验将评估VVD-130850作为单一药物并结合免疫检查点抑制治疗晚期实体瘤和血液肿瘤患者的安全性，耐受性，药代动力学，药效学和初步抗肿瘤活性。。

“We are excited to announce the initiation and dosing of this highly selective STAT3 inhibitor,” said Jenna Goldberg, M.D., Chief Medical Officer of Vividion. “What makes this clinical candidate really outstanding in our minds is that it binds to STAT3 to inhibit the expression of downstream target genes without affecting the STAT3 protein levels.

Vividion首席医疗官JennaGoldberg医学博士说：“我们很高兴宣布这种高选择性STAT3抑制剂的启动和剂量。”。“在我们看来，这种临床候选者真正突出的是它与STAT3结合，抑制下游靶基因的表达，而不影响STAT3蛋白水平。

We believe the STAT3 pathway holds promise to shift the treatment paradigm for cancer patients and look forward to advancing VVD-130850 through clinical development.”.

我们相信STAT3途径有望改变癌症患者的治疗模式，并期待通过临床开发推进VVD-130850。”。

The company is advancing multiple novel drug discovery programs toward the clinic and has more than a dozen similar pipeline opportunities emerging in early discovery in the fields of oncology and immunology. Following the company’s acquisition by Bayer in August 2021, Vividion is operating at arm’s length in a best-of-both-worlds’ model, preserving its innovative, entrepreneurial culture while also leveraging Bayer’s deep expertise in small molecule drug development, global capabilities and financial strength..

该公司正在向临床推进多项新药发现计划，并且在肿瘤学和免疫学领域的早期发现中出现了十多个类似的管道机会。2021年8月，公司被拜耳收购后，Vividion正以“两全其美”的模式开展业务，保持其创新创业文化，同时利用拜耳在小分子药物开发、全球能力和财务实力方面的深厚专业知识。。

About STAT3

关于STAT3

Signal transducer and activator of transcription 3 (STAT3) is a key regulatory protein, which become hyperactivated in certain human cancers where it can promote tumor progression, metastasis, and decreased immune responses. Owing to its role in tumor formation, metastasis as well as drug resistance and immunosuppression, the STAT3 pathway is recognized as a promising therapeutic target in a wide range of cancers..

信号转导和转录激活因子3（STAT3）是一种关键的调节蛋白，在某些人类癌症中会过度活化，从而促进肿瘤进展，转移和免疫反应降低。由于其在肿瘤形成，转移以及耐药性和免疫抑制中的作用，STAT3途径被认为是多种癌症中有希望的治疗靶点。。

About Vividion

关于Vividion

Vividion Therapeutics, Inc. a wholly owned and independently operated subsidiary of Bayer AG acquired in August 2021, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics，Inc.是拜耳公司（Bayer AG）于2021年8月收购的全资独立运营子公司，是一家生物制药公司，利用新的发现技术开发高价值，传统上不可药用的靶点，用于精确治疗毁灭性癌症和免疫紊乱。

The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets.

该公司的平台使其能够在涉及多种疾病的经过充分验证的蛋白质靶标上识别数百个以前未知的功能口袋，同时从其专有的共价化学文库中识别与这些口袋高度选择性相互作用的化合物。

The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com..

该公司正在利用其专有的化学蛋白质组学平台，推进针对肿瘤学和免疫学中高价值，传统上不可药用靶标的高选择性小分子治疗剂的多样化管道。欲了解更多信息，请访问www.vividion.com。。

About Bayer

拜耳简介

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses.

拜耳是一家全球性企业，在医疗保健和营养等生命科学领域拥有核心竞争力。它的产品和服务旨在通过支持应对全球人口不断增长和老龄化所带来的重大挑战，帮助人类和地球繁荣发展。拜耳致力于推动可持续发展，并对其业务产生积极影响。

At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

与此同时，该集团旨在通过创新和增长来提高其盈利能力和创造价值。拜耳品牌代表着全世界的信任、可靠性和质量。2022财年，该集团雇佣了约101000名员工，销售额为507亿欧元。不含特殊项目的研发费用为62亿欧元。

For more information, go to www.bayer.com..

欲了解更多信息，请访问www.bayer.com。。

Find more information at https://pharma.bayer.com/

更多信息，请访问https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Facebook: http://www.facebook.com/bayer

ls (2024-0005e)

ls（2024-0005e）

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本版本可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来业绩、财务状况、发展或业绩与此处给出的估计之间存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments..

这些因素包括拜耳网站www.Bayer.com上拜耳公开报告中讨论的因素。公司不承担更新这些前瞻性声明或使其符合未来事件或发展的任何责任。。